An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Leuprorelin (Primary)
- Indications Precocious puberty
- Focus Therapeutic Use
- Sponsors Tolmar
- 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
- 09 Jun 2015 New trial record